Allworth Financial’s Xenon Pharmaceuticals XENE Stock Holding History

Allworth Financial’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51K	Sell	25 -13	-34%	-$722	﹤0.01%	4603
2026 Q1	$2.21K	Sell	38 -78	-67%	-$3.59K	﹤0.01%	4321
2025 Q4	$5.2K	Sell	116 -10	-8%	-$420	﹤0.01%	3679
2025 Q3	$5.06K	Buy	126 +91	+260%	+$3.21K	﹤0.01%	3540
2025 Q2	$1.1K	Buy	35 +23	+192%	+$750	﹤0.01%	3936
2025 Q1	$459	Hold	12	–	–	﹤0.01%	3702
2024 Q4	$471	Hold	12	–	–	﹤0.01%	3619
2024 Q3	$473	Buy	12 +7	+140%	+$282	﹤0.01%	3434
2024 Q2	$214	Sell	5 -7	-58%	-$280	﹤0.01%	3541
2024 Q1	$517	Buy	+12	New	+$552	﹤0.01%	3285

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Allworth Financial's XENE Position: Q2 2026 in Review

Allworth Financial reduced its Xenon Pharmaceuticals (XENE) stake by 34% in Q2 2026, selling an estimated $722 and leaving 25 shares worth $1.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4603.

Allworth Financial first reported a position in XENE in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.2K in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Allworth Financial held 25 shares of Xenon Pharmaceuticals worth $1.51K as of Q2 2026.
Allworth Financial sold 13 Xenon Pharmaceuticals shares in Q2 2026, an estimated $722.
Xenon Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4603 holding.
Allworth Financial first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Allworth Financial's Xenon Pharmaceuticals position peaked at $5.2K in Q4 2025.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.